Can PepFold design peptides for rs12255372?

Yes. PepFold accepts rs12255372 as input, annotates it via ClinVar, maps it to the TCF7L2 protein via UniProt, generates peptide candidates targeting affected functional domains, predicts their 3D structures with ESMFold, and produces a scored report with Fmoc-SPPS synthesis protocols.

SNP Database

rs12255372 — TCF7L2 Intron 4 (G>T)

Q: What gene is rs12255372 in?

rs12255372 is a variant in the TCF7L2 (Transcription Factor 7-Like 2) gene located on chromosome 10q25.2. Key transcription factor in the Wnt signaling pathway. Regulates incretin hormone expression (GLP-1, GIP) and pancreatic beta-cell proliferation and function.

Q: What is the clinical significance of rs12255372?

rs12255372 is classified as "Risk factor" in ClinVar. TCF7L2 is a transcription factor in the Wnt signaling pathway that regulates incretin hormone (GLP-1, GIP) expression and pancreatic beta-cell proliferation. The risk allele likely alters alternative splicing, reducing GLP-1 secretion and impairing glucose-stimulated insulin release.

Risk factor · ~27% global allele frequency (T allele)

rs12255372 in TCF7L2 is the strongest common genetic risk factor for type 2 diabetes, with an odds ratio of ~1.4 per T allele. Discovered in the landmark 2006 Grant et al. Nature Genetics study, it has been replicated across all major ethnic groups.

Molecular Mechanism

TCF7L2 is a transcription factor in the Wnt signaling pathway that regulates incretin hormone (GLP-1, GIP) expression and pancreatic beta-cell proliferation. The risk allele likely alters alternative splicing, reducing GLP-1 secretion and impairing glucose-stimulated insulin release.

Peptide Therapeutic Relevance

GLP-1 receptor agonist peptides (semaglutide, liraglutide, tirzepatide) are blockbuster therapeutics for diabetes and obesity. PepFold generates novel peptide candidates in this validated therapeutic class.

Gene: TCF7L2 (Transcription Factor 7-Like 2)

Key transcription factor in the Wnt signaling pathway. Regulates incretin hormone expression (GLP-1, GIP) and pancreatic beta-cell proliferation and function.

Chromosome 10q25.2

Full TCF7L2 gene profile →

Condition: Type 2 Diabetes

A metabolic disorder characterized by insulin resistance and progressive beta-cell dysfunction. TCF7L2 variants are the strongest common genetic risk factors. GLP-1 receptor agonist peptides have revolutionized treatment.

Prevalence: ~537 million adults worldwide (IDF 2021), ~10.5% of global adult population

Full Type 2 Diabetes profile →

Related Variants

rs7903146TCF7L2 — Intron 3 (C>T)

Analyze rs12255372 with PepFold

Submit rs12255372 and get ranked peptide candidates with 3D structures and synthesis protocols in under 2 minutes.

Try Analysis View Pricing